The Experimental Study In Treatment With DC Against Prostate Cancer

PURPOSES: Injection of human cord blood mononuclear cells (hu- CBMNC) can result in a stable long-term reconstitution of a functional human immune system in mice with severe combined immunodeficiency (SCJD). This experimental model was used to assess the ability of dendritic cells (DCs) pulsed with antigen of PC-3 cells to against prostate cancer (PCa). METHODS: I) Six to 8-week-old male SCID mice were maintained under special pathogen梖ree (SPF) conditions. CBMNC were collected from heparinized cord blood. SCID mice were injected intraperitoneally with 2 X l0~ CBMNC resuspended in 0.5m1 phosphate-buffered saline (PBS). At 2 weeks after reconstitution, only mice that tested positive for human Ig in serum were considered for the study. 2) For production of tumor, PC-3 cells were injected subcutaneously into the flanks of SCID mice. The tumor volume (v) were monitored eveiy 2 days and PSA in serum were assayed every 2 weeks. 3) The incubation condition of DC from CBMNC was rhGM-CSF l000u/ml and rhIL-4 500u/ml. The culture time of DC was 3-4 week.4) Hu-CBMNC-SCID mice beared prostate cancer were given DCs pulsed with PC-3 cells frozen repeatedly generated from human cord blood with diffet-ent cell quantity (106,1 O~, 108) and different way (administrated via tail vein, intratumoral). The SCID mice in control group were given NS/esreogen. The tumor volume and survivai time and PSA of serum were recorded and compared with the control groups by X2 test. III -v RESULTS: The mice in intravenous groups (106,1 0~) and in intratumoral group led to significant regression of established tumors and significant prolonged survival. (P<0.05, P<0.001, P<0.0l respectively, X2 test). The PSA of mice in therapeutic groups descended significantly that compared with the control group. CONCLUSiONS: The results indicate that DC pulsed with tumor cells mixture as a source of tumor antigen can induce an effective antitumor immune response. These findings provide a rational and protocol for the use of cultured DC in immunotherapy of prostate cancer.